表紙
市場調査レポート

大日本住友製薬の製品パイプライン分析

Sumitomo Dainippon Pharma Co., Ltd. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 321961
出版日 ページ情報 英文 102 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
大日本住友製薬の製品パイプライン分析 Sumitomo Dainippon Pharma Co., Ltd. - Product Pipeline Review - 2015
出版日: 2015年09月30日 ページ情報: 英文 102 Pages
概要

大日本住友製薬では中枢神経系(CNS)、心血管系、糖尿病、癌、感染症などの領域における様々なファーマシューティカル製品を開発・製造・商品化しています。また、動物用医薬品、食品添加物、診断用薬、研究用材料等の提供、さらに研究本部では革新的な新薬研究を行っています。

当レポートでは、大日本住友製薬 における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

大日本住友製薬 の基本情報

  • 大日本住友製薬 の概要
  • 主要情報
  • 企業情報

大日本住友製薬 :R&Dの概要

  • 主な治療範囲

大日本住友製薬 :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

大日本住友製薬 :パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 登録申請前の製品/併用療法モダリティ
    • 第3相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

大日本住友製薬 :薬剤プロファイル

  • amrubicin hydrochloride
  • blonanserin
  • droxidopa
  • lurasidone hydrochloride
  • ranirestat
  • vatiquinone
  • afacifenacin
  • DSP-6952
  • obeticholic acid
  • zonisamide
  • EPI-589
  • WT-2725
  • WT-4869
  • DSP-0011
  • DSR-6434
  • NEP-28
  • SM-276001
  • SM-295291
  • SM-324405
  • SM-369926
  • Small Molecule to Agonize Muscarinic Acetylcholine Receptor 4 for Schizophrenia
  • Small Molecule to Inhibit Soluble Epoxide Hydrolase for Renal Protection
  • Small Molecules to Activate Translocator Protein for Anxiety
  • Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis
  • Small Molecules to Inhibit Phosphodiesterase 4 for Asthma and Inflammation
  • Small Molecules to Target Ras Signaling Pathway for Cancer
  • Apoptosis Inhibitor Of Macrophages
  • HLS-001
  • Small Molecule to Antagonize GCGR for Type 2 Diabetes
  • Small Molecule to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes
  • Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease
  • Small Molecules to Inhibit CaMKII for Undisclosed Indication
  • Small Molecules to Inhibit mPGES-1 for Inflammation

大日本住友製薬 :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

大日本住友製薬 :最新のパイプライン情報

大日本住友製薬 :開発が休止されたプロジェクト

大日本住友製薬 :開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • emapunil
    • rafabegron
    • ceftaroline fosamil
    • DSP-0565
    • DSP-3025
    • DSP-7238
    • DSP-9599
    • KGA-3235
    • limaprost
    • rafabegron
    • ranirestat
    • resequinil
    • rimacalib
    • SEP-225425
    • SEP-226332
    • SEP-227162
    • SEP-227900
    • SMP-028
    • SMP-797

大日本住友製薬 :企業理念

大日本住友製薬 :本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07612CDB

Summary

Global Markets Direct's, 'Sumitomo Dainippon Pharma Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the Sumitomo Dainippon Pharma Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sumitomo Dainippon Pharma Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Sumitomo Dainippon Pharma Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Sumitomo Dainippon Pharma Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Sumitomo Dainippon Pharma Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate Sumitomo Dainippon Pharma Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Sumitomo Dainippon Pharma Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Sumitomo Dainippon Pharma Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Sumitomo Dainippon Pharma Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sumitomo Dainippon Pharma Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Sumitomo Dainippon Pharma Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Sumitomo Dainippon Pharma Co., Ltd. Snapshot
    • Sumitomo Dainippon Pharma Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Sumitomo Dainippon Pharma Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products Glance
    • Sumitomo Dainippon Pharma Co., Ltd. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Sumitomo Dainippon Pharma Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Sumitomo Dainippon Pharma Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Sumitomo Dainippon Pharma Co., Ltd. - Drug Profiles
    • amrubicin hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • blonanserin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lurasidone hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ranirestat
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • zonisamide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vatiquinone
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • afacifenacin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DSP-6952
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • obeticholic acid
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DSP-7888
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • WT-4869
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EPI-589
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • WT-2725
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DSP-0011
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DSR-6434
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DSR-71167
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DSR-98776
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NEP-28
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SM-276001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SM-295291
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SM-324405
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SM-369926
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize Muscarinic Acetylcholine Receptor 4 for Schizophrenia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Soluble Epoxide Hydrolase for Renal Protection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate Translocator Protein for Anxiety
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Phosphodiesterase 4 for Asthma and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Target Ras Signaling Pathway for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug to Inhibit Apoptosis of Macrophages for Metabolic Syndrome
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DSR-17759
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HLS-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit CaMKII for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit mPGES-1 for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Analysis
    • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Target
    • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Route of Administration
    • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Molecule Type
    • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Mechanism of Action
  • Sumitomo Dainippon Pharma Co., Ltd. - Recent Pipeline Updates
  • Sumitomo Dainippon Pharma Co., Ltd. - Dormant Projects
  • Sumitomo Dainippon Pharma Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • emapunil
      • rafabegron
      • ceftaroline fosamil
      • DSP-0565
      • DSP-3025
      • DSP-7238
      • DSP-9599
      • KGA-3235
      • limaprost
      • rafabegron
      • ranirestat
      • resequinil
      • rimacalib
      • SEP-225425
      • SEP-226332
      • SEP-227162
      • SEP-227900
      • SMP-028
      • SMP-797
  • Sumitomo Dainippon Pharma Co., Ltd. - Company Statement
  • Sumitomo Dainippon Pharma Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Sumitomo Dainippon Pharma Co., Ltd., Key Information
  • Sumitomo Dainippon Pharma Co., Ltd., Key Facts
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Indication, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Stage of Development, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Partnered Products in Pipeline, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Out-Licensed Products in Pipeline, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pre-Registration, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Phase III, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Phase II, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Phase I, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Preclinical, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Discovery, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Target, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Route of Administration, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Molecule Type, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Recent Pipeline Updates, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Dormant Developmental Projects,2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Discontinued Pipeline Products, 2015
  • Sumitomo Dainippon Pharma Co., Ltd., Other Locations
  • Sumitomo Dainippon Pharma Co., Ltd., Subsidiaries

List of Figures

  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Top 10 Indication, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Stage of Development, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Partnered Products in Pipeline, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Out-Licensed Products in Pipeline, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Top 10 Target, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top